EGFR	B:C1739039
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	B:C1171362
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	B:C0178719
domain	O
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	O
domain	B:C1514562
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	B:C0003241
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	O
and	O
PTEN	B:C1430988
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	B:C0149782
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

EGFR	O
protein	I:C1739039
expression	O
using	O
a	O
specific	O
intracellular	O
domain	O
antibody	O
and	O
PTEN	O
and	O
clinical	O
outcomes	O
in	O
squamous	O
cell	I:C0149782
lung	I:C0149782
cancer	I:C0149782
patients	O
with	O
EGFR	B:C3899317
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
therapy	I:C3899317
.	O

The	O
aim	O
of	O
this	O
research	B:C0035168
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	B:C0582103
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	B:C3899317
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	B:C3899317
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	B:C0332154
patients	O
with	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	B:C0149782
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

The	O
aim	O
of	O
this	O
research	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
clinical	O
features	O
that	O
are	O
related	O
with	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
(	O
EGFR	O
-	I:C3899317
tyrosine	I:C3899317
kinase	I:C3899317
inhibitor	I:C3899317
)	O
efficacy	O
in	O
previously	O
treated	O
patients	O
with	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
(	O
squamous	B:C0149782
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
)	O
.	O

This	O
retrospective	B:C0035363
study	I:C0035363
included	O
67	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
with	O
obtainable	O
lung	O
cancer	I:C0684249
tissue	O
and	O
records	O
on	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
response	O
and	O
survival	O
.	O

This	O
retrospective	O
study	I:C0035363
included	O
67	O
squamous	B:C0149782
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
with	O
obtainable	O
lung	O
cancer	I:C0684249
tissue	O
and	O
records	O
on	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
response	O
and	O
survival	O
.	O

This	O
retrospective	O
study	I:C0035363
included	O
67	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
with	O
obtainable	O
lung	B:C0684249
cancer	I:C0684249
tissue	O
and	O
records	O
on	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
response	O
and	O
survival	O
.	O

This	O
retrospective	O
study	I:C0035363
included	O
67	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
with	O
obtainable	O
lung	O
cancer	I:C0684249
tissue	B:C0040300
and	O
records	O
on	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
response	O
and	O
survival	O
.	O

This	O
retrospective	O
study	I:C0035363
included	O
67	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
with	O
obtainable	O
lung	O
cancer	I:C0684249
tissue	O
and	O
records	B:C0034869
on	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
response	O
and	O
survival	O
.	O

This	O
retrospective	O
study	I:C0035363
included	O
67	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
with	O
obtainable	O
lung	O
cancer	I:C0684249
tissue	O
and	O
records	O
on	O
EGFR	B:C3899317
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
response	O
and	O
survival	O
.	O

EGFR	B:C1739039
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	B:C1171362
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	B:C0684249
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	B:C0040300
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	B:C0021044
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	B:C0003241
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	B:C0524637
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	B:C0178719
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	B:C1514562
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	B:C1514562
domain	I:C1514562
)	O
of	O
EGFR	O
.	O

EGFR	O
protein	I:C1739039
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
with	O
a	O
specific	O
antibody	O
that	O
recognizes	O
the	O
intracellular	O
domain	O
(	O
intracellular	O
domain	I:C1514562
)	O
of	O
EGFR	B:C1739039
.	O

PTEN	B:C1430988
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
also	O
evaluated	O
with	O
immunohistochemistry	O
.	O

PTEN	O
expression	B:C1171362
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
also	O
evaluated	O
with	O
immunohistochemistry	O
.	O

PTEN	O
expression	O
in	O
lung	B:C0684249
cancer	I:C0684249
tissue	O
was	O
also	O
evaluated	O
with	O
immunohistochemistry	O
.	O

PTEN	O
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	B:C0040300
was	O
also	O
evaluated	O
with	O
immunohistochemistry	O
.	O

PTEN	O
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
also	O
evaluated	B:C0220825
with	O
immunohistochemistry	O
.	O

PTEN	O
expression	O
in	O
lung	O
cancer	I:C0684249
tissue	O
was	O
also	O
evaluated	O
with	O
immunohistochemistry	B:C0021044
.	O

PI3KCA	B:C3273085
gene	I:C3273085
amplification	I:C3273085
was	O
detected	O
by	O
quantitative	O
real	I:C3179034
-	I:C3179034
time	I:C3179034
polymerase	I:C3179034
chain	I:C3179034
reaction	I:C3179034
,	O
and	O
FGFR1	O
amplification	I:C1517090
was	O
assessed	O
by	O
fluorescent	O
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
.	O

PI3KCA	O
gene	I:C3273085
amplification	I:C3273085
was	O
detected	B:C0442726
by	O
quantitative	O
real	I:C3179034
-	I:C3179034
time	I:C3179034
polymerase	I:C3179034
chain	I:C3179034
reaction	I:C3179034
,	O
and	O
FGFR1	O
amplification	I:C1517090
was	O
assessed	O
by	O
fluorescent	O
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
.	O

PI3KCA	O
gene	I:C3273085
amplification	I:C3273085
was	O
detected	O
by	O
quantitative	B:C3179034
real	I:C3179034
-	I:C3179034
time	I:C3179034
polymerase	I:C3179034
chain	I:C3179034
reaction	I:C3179034
,	O
and	O
FGFR1	O
amplification	I:C1517090
was	O
assessed	O
by	O
fluorescent	O
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
.	O

PI3KCA	O
gene	I:C3273085
amplification	I:C3273085
was	O
detected	O
by	O
quantitative	O
real	I:C3179034
-	I:C3179034
time	I:C3179034
polymerase	I:C3179034
chain	I:C3179034
reaction	I:C3179034
,	O
and	O
FGFR1	B:C1517090
amplification	I:C1517090
was	O
assessed	O
by	O
fluorescent	O
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
.	O

PI3KCA	O
gene	I:C3273085
amplification	I:C3273085
was	O
detected	O
by	O
quantitative	O
real	I:C3179034
-	I:C3179034
time	I:C3179034
polymerase	I:C3179034
chain	I:C3179034
reaction	I:C3179034
,	O
and	O
FGFR1	O
amplification	I:C1517090
was	O
assessed	O
by	O
fluorescent	B:C0162789
in	I:C0162789
situ	I:C0162789
hybridization	I:C0162789
.	O

EGFR	B:C1739039
intracellular	O
domain	I:C1514562
expression	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
(	I:C1520224
ECOG	I:C1520224
)	I:C1520224
performance	I:C1520224
status	I:C1520224
(	I:C1520224
PS	I:C1520224
)	I:C1520224
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	O
-	O
free	O
survival	O
following	O
EGFR	O
-	I:C3899317
TKIs	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
intracellular	B:C1514562
domain	I:C1514562
expression	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
(	I:C1520224
ECOG	I:C1520224
)	I:C1520224
performance	I:C1520224
status	I:C1520224
(	I:C1520224
PS	I:C1520224
)	I:C1520224
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	O
-	O
free	O
survival	O
following	O
EGFR	O
-	I:C3899317
TKIs	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
intracellular	O
domain	I:C1514562
expression	B:C1171362
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
(	I:C1520224
ECOG	I:C1520224
)	I:C1520224
performance	I:C1520224
status	I:C1520224
(	I:C1520224
PS	I:C1520224
)	I:C1520224
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	O
-	O
free	O
survival	O
following	O
EGFR	O
-	I:C3899317
TKIs	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
intracellular	O
domain	I:C1514562
expression	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	B:C1520224
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
(	I:C1520224
ECOG	I:C1520224
)	I:C1520224
performance	I:C1520224
status	I:C1520224
(	I:C1520224
PS	I:C1520224
)	I:C1520224
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	O
-	O
free	O
survival	O
following	O
EGFR	O
-	I:C3899317
TKIs	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
intracellular	O
domain	I:C1514562
expression	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
(	I:C1520224
ECOG	I:C1520224
)	I:C1520224
performance	I:C1520224
status	I:C1520224
(	I:C1520224
PS	I:C1520224
)	I:C1520224
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	B:C0178874
-	O
free	O
survival	O
following	O
EGFR	O
-	I:C3899317
TKIs	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
intracellular	O
domain	I:C1514562
expression	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.53	O
,	O
P=0.022	O
)	O
and	O
Eastern	O
Cooperative	I:C1520224
Oncology	I:C1520224
Group	I:C1520224
(	I:C1520224
ECOG	I:C1520224
)	I:C1520224
performance	I:C1520224
status	I:C1520224
(	I:C1520224
PS	I:C1520224
)	I:C1520224
(	O
HR	O
0.43	O
,	O
P=0.022	O
)	O
were	O
significantly	O
related	O
with	O
progression	O
-	O
free	O
survival	O
following	O
EGFR	B:C3899317
-	I:C3899317
TKIs	I:C3899317
treatment	I:C3899317
.	O

PTEN	B:C1430988
expression	O
(	O
HR	O
0.52	O
,	O
P=0.025	O
)	O
was	O
significantly	O
related	O
to	O
overall	O
survival	O
.	O

PTEN	O
expression	B:C1171362
(	O
HR	O
0.52	O
,	O
P=0.025	O
)	O
was	O
significantly	O
related	O
to	O
overall	O
survival	O
.	O

The	O
group	O
of	O
EGFR	B:C1739039
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	B:C1446409
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	B:C1430988
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	B:C1446409
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	B:C1520224
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	B:C1333602
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	B:C1739039
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	B:C0205160
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	B:C1430988
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	B:C0205160
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	B:C1520224
PS	I:C1520224
with	O
longer	O
median	O
progression	O
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

The	O
group	O
of	O
EGFR	O
-	O
positive	O
or	O
PTEN	O
-	O
positive	O
patients	O
with	O
ECOG	O
PS	I:C1520224
of	O
0	O
or	O
1	O
had	O
better	O
clinical	I:C1333602
outcomes	I:C1333602
than	O
patients	O
who	O
were	O
EGFR	O
-	O
negative	O
and	O
PTEN	O
-	O
negative	O
or	O
who	O
had	O
poor	O
ECOG	O
PS	I:C1520224
with	O
longer	O
median	O
progression	B:C0178874
-	O
free	O
survival	O
(	O
2.1	O
vs	O
1.0	O
months	O
,	O
P=0.05	O
)	O
and	O
overall	O
survival	O
(	O
6.2	O
vs	O
2.1	O
months	O
,	O
P=0.05	O
)	O
.	O

EGFR	B:C1739039
expression	O
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	O
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	B:C1171362
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	O
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	O
using	O
an	O
intracellular	B:C1514562
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	O
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	O
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	B:C0003241
and	O
PTEN	O
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	O
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	B:C1430988
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	O
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	O
protein	I:C1430988
expression	B:C1171362
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	O
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	O
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	B:C0149782
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	O
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

EGFR	O
expression	O
using	O
an	O
intracellular	O
domain	I:C1514562
-	O
specific	O
antibody	O
and	O
PTEN	O
protein	I:C1430988
expression	O
may	O
be	O
used	O
to	O
identify	O
squamous	O
cell	I:C0149782
carcinoma	I:C0149782
of	I:C0149782
the	I:C0149782
lung	I:C0149782
patients	O
who	O
might	O
benefit	O
from	O
EGFR	B:C3899317
-	I:C3899317
TKI	I:C3899317
treatment	I:C3899317
.	O

